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Abstract
Aims: The aim of this study was to identify predictors of adverse events among patients with ST-elevation 
myocardial infarction (STEMI) undergoing contemporary primary percutaneous coronary intervention (PCI).
Methods and results: Individual data of 2,655 patients from two primary PCI trials (EXAMINATION, 
N=1,504; COMFORTABLE AMI, N=1,161) with identical endpoint definitions and event adjudication were 
pooled. Predictors of all-cause death or any reinfarction and definite stent thrombosis (ST) and target lesion 
revascularisation (TLR) outcomes at one year were identified by multivariable Cox regression analysis. 
Killip class III or IV was the strongest predictor of all-cause death or any reinfarction (OR 5.11, 95% CI: 
2.48-10.52), definite ST (OR 7.74, 95% CI: 2.87-20.93), and TLR (OR 2.88, 95% CI: 1.17-7.06). Impaired 
left ventricular ejection fraction (OR 4.77, 95% CI: 2.10-10.82), final TIMI flow 0-2 (OR 1.93, 95% CI: 1.05-
3.54), arterial hypertension (OR 1.69, 95% CI: 1.11-2.59), age (OR 1.68, 95% CI: 1.41-2.01), and peak CK 
(OR 1.25, 95% CI: 1.02-1.54) were independent predictors of all-cause death or any reinfarction. Allocation 
to treatment with DES was an independent predictor of a lower risk of definite ST (OR 0.35, 95% CI: 0.16-
0.74) and any TLR (OR 0.34, 95% CI: 0.21-0.54).
Conclusions: Killip class remains the strongest predictor of all-cause death or any reinfarction among 
STEMI patients undergoing primary PCI. DES use independently predicts a lower risk of TLR and defi-
nite ST compared with BMS. The COMFORTABLE AMI trial is registered at: http://www.clinicaltrials.gov/
ct2/show/NCT00962416. The EXAMINATION trial is registered at: http://www.clinicaltrials.gov/ct2/show/
NCT00828087
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Introduction
Mortality after acute ST-segment elevation myocardial infarc-
tion (STEMI) has considerably declined during the last two dec-
ades owing to improved access to and the widespread use of 
reperfusion therapy1. Primary percutaneous coronary intervention 
(PCI) has emerged as the reperfusion therapy of choice due to its 
lower risk of reinfarction and haemorrhagic stroke and improved 
vessel patency, translating into lower mortality as compared to 
fibrinolysis2. However, cardiac mortality is still observed in up to 
4% of patients undergoing primary PCI at one-year follow-up3,4. 
Moreover, STEMI patients undergoing primary PCI remain at risk 
for reinfarction, stent thrombosis and repeat revascularisation, 
underlining the need to identify predictors of adverse clinical out-
comes in this high-risk population.
The impact of clinical characteristics on prognosis among 
STEMI patients has been investigated in numerous studies during 
the fibrinolysis era, which consistently identified Killip class, age, 
heart rate, and anterior MI as independent predictors of mortality5,6. 
More recently, impaired left ventricular ejection fraction (LVEF) and 
angiographic variables – such as multivessel disease and small ves-
sel diameter – have been reported to predict mortality among STEMI 
patients undergoing primary PCI7,8. However, these findings were 
based on studies without systematic use of P2Y12 receptor inhibi-
tors, thrombus aspiration and stent implantation, which have signifi-
cantly improved clinical outcomes9-13,14. In addition, the results of two 
large-scale randomised clinical trials have recently suggested that 
the use of new-generation drug-eluting stents (DES) among STEMI 
patients undergoing primary PCI is associated with a lower risk of 
repeat revascularisation, reinfarction and stent thrombosis (ST) com-
pared with bare metal stents through to one year15,16. The purpose 
of the present study was therefore to identify predictors of all-cause 
death or any reinfarction and definite ST, target lesion revascular-
isation (TLR) among patients with STEMI undergoing primary 
PCI in a pooled analysis of two contemporary primary PCI trials 
(EXAMINATION and COMFORTABLE AMI)15,16.
Methods
PATIENT POPULATION
Individual patient data from COMFORTABLE AMI and 
EXAMINATION were pooled for the purpose of the present study. 
The details and primary results of the COMFORTABLE AMI and 
EXAMINATION trials have been described previously15,16. In sum-
mary, 1,161 STEMI patients undergoing primary PCI at 11 sites 
in Europe and Israel between September 2009 and January 2011 
were randomly assigned to treatment with biolimus-eluting stents 
with biodegradable polymer coating (BioMatrix™; Biosensors 
Europe SA, Morges, Switzerland), or bare metal stents (Gazelle™; 
Biosensors Europe SA) in the COMFORTABLE AMI trial. In the 
EXAMINATION trial, 1,504 STEMI patients undergoing primary 
PCI at 12 sites in Europe between December 2008 and May 2010 
were randomly assigned to treatment with everolimus-eluting stents 
with durable polymer coating (XIENCE V; Abbott Vascular, Santa 
Clara, CA, USA), or bare metal stents (MULTI-LINK VISION™; 
Abbott Vascular). Overall, 10 out of 2,665 patients withdrew con-
sent after randomisation (six patients in EXAMINATION and four 
patients in COMFORTABLE AMI). For the purpose of this analy-
sis, 2,655 patients allocated to new-generation DES (N=1,326) or 
bare metal stents (N=1,329) were pooled. A summary of the princi-
pal trial characteristics is reported in Table 1.
ENDPOINT DEFINITIONS AND EVENT ADJUDICATION
The same clinical endpoint definitions were used in COMFORTABLE 
AMI and EXAMINATION15,16. All-cause mortality included cardiac 
death, vascular death, and non-cardiovascular death. All deaths were 
considered cardiac unless an unequivocal non-cardiac cause could be 
established. Reinfarction was defined according to the WHO extended 
historical definition17. Target lesion revascularisation (TLR) was 
defined as any repeat revascularisation due to a stenosis within the 
index stent or within a 5 mm border proximal and distal to the index 
stent. Stent thrombosis (ST) was defined according to the Academic 
Research Consortium criteria18. In both the COMFORTABLE AMI 
Table 1. Summary of included trials.
Study
No. of 
patients
Stent 
type
Primary 
endpoint
Inclusion 
criteria
Exclusion criteria
Baseline characteristics
Mean age, years (SD)
M
ale,%
Diabetes,%
LVEF, m
ean
Hyperlipidaem
ia, %
Hypertension, %
Sm
oking, %
Fam
ily history, %
Clinical follow-up
COMFORTABLE 
AMI
1,161 BES 
vs. 
BMS
Composite of 
cardiac death, 
target vessel MI, 
clinically indicated 
TLR at 1 year
Primary PCI 
within 24 hours, 
evidence of 
ischaemia
Age <18, intolerance to 
medication, use of vitamin K 
agents secondary to ST, 
mechanical complications, 
planned surgery within 6 months
60.6 
(11.7)
79.3 15.0 49.5 56.4 47.0 49.5 32.1 1 year
EXAMINATION 1,504 EES 
vs. 
BMS
Composite of 
death, any MI, TVR 
at 1 year
Primary PCI 
within 48 hours, 
evidence of 
ischaemia
Age <18, intolerance to 
medication, use of vitamin K 
agents secondary to ST
61.2 
(12.5)
83.0 17.2 51.1 43.7 48.4 72.2 16.8 1 year
BES: biolimus-eluting stent; BMS: bare metal stent; EES: everolimus-eluting stent; LVEF: left ventricular ejection fraction; MI: myocardial infarction; PCI: percutaneous coronary intervention; 
SD: standard deviation; ST: stent thrombosis; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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and EXAMINATION trials, adverse events were independently adju-
dicated by a clinical events committee, chaired by the same investiga-
tor (PV), unaware of treatment allocation. The pre-specified primary 
endpoint of the present analysis was the composite of all-cause death 
and any reinfarction. Secondary endpoints were definite ST and tar-
get lesion revascularisation. Angiograms were centrally assessed by 
the independent core laboratory at Bern University Hospital, Bern, 
Switzerland, and Cardialysis, Rotterdam, The Netherlands by per-
sonnel blinded to stent type and outcome. Killip class I includes 
patients without clinical signs of heart failure. Killip class II includes 
patients with rales or crackles of <50% in both lung fields as well 
as the presence of an audible S3 heart sound, and elevated jugular 
venous pressure. Killip class III includes patients with rales or crack-
les of >50% in both lung fields as well as the presence of an audible 
S3 heart sound, and elevated jugular venous pressure. Killip class IV 
includes patients in cardiogenic shock or hypotension, and evidence 
of peripheral vasoconstriction.
STATISTICAL METHODS
For the purpose of the present study, patient-level data from the 
EXAMINATION and COMFORTABLE AMI trials were pooled 
and analysed. Continuous variables are expressed as means±standard 
deviation and compared by means of ANOVA. Categorical data are 
expressed as frequencies and percentages and are compared using the 
χ2 and Fisher’s exact tests. Mixed effects logistic regressions with ran-
dom effect of the study (EXAMINATION or COMFORTABLE AMI) 
were used for the analyses of all-cause death or any reinfarction, TLR 
or definite ST. Odds ratios (OR) with 95% confidence intervals (95% 
CI) are reported. Univariable and multivariable mixed effects logistic 
regressions tested the association of single and multiple risk factors, 
respectively, with outcomes of interest (all-cause death or any reinfarc-
tion, TLR and definite ST). Multivariable risk factors with a p-value 
below 0.05 were retained for each minimal model, with OR (95% CI) 
reported. Estimates for the multivariable and minimal models are after 
multiple imputation of missing data per study using chained equa-
tions. For illustrative purposes, a classification and regression tree 
(CART) for time-to-death or reinfarction was constructed from the 
minimal model (with splits set at p-value <0.05, with each group after 
the split including a minimum of 10 patients and/or 10 events) using 
non-missing data only. All p-values shown are from two-sided tests, 
and the level of statistical significance was set at 0.05. Analyses were 
performed using Stata 12 (StataCorp, College Station, TX, USA).
Results
One-year follow-up was available in 2,617 of 2,655 patients 
(98.6%). At one year, the composite of all-cause death and any rein-
farction occurred in 144 patients (5.4%), definite ST in 35 patients 
(1.3%), and TLR in 96 patients (3.6%).
PREDICTORS OF ALL-CAUSE DEATH AND ANY REINFARCTION
Baseline clinical, angiographic, and procedural characteristics 
according to the occurrence of all-cause death or any reinfarction 
at one year are summarised in Table 2. Patients who experienced 
Table 2. Baseline characteristics of patients with and without 
all-cause death or any reinfarction at one year.
All-cause death or any reinfarction
Yes (N=144) No (N=2,511) p-value
Age (yrs) 69.6±13.0 60.43±11.88 <0.001
Male gender 96 (66.7%) 2,066 (82.3%) <0.001
Body mass index (kg/m2) 26.9±4.6 27.3±4.0 0.22
Heart rate on admission 80.4±18.1 76.3±16.6 0.004
Blood pressure - systolic (mmHg) 126.4±28.1 127.7±23.1 0.54
Hypertension 97 (67.4%) 1,172 (46.7%) <0.001
Family history of CAD 28 (20.9%) 597 (25.0%) 0.35
Smoking at baseline 50 (35.2%) 1,281 (51.3%) <0.001
Dyslipidaemia 70 (49.0%) 1,237 (49.4%) 0.93
Diabetes mellitus 41 (28.5%) 391 (15.6%) <0.001
Left ventricular ejection fraction <30% 14 (13.0%) 27 (1.3%) <0.001
Previous MI 15 (10.4%) 128 (5.1%) 0.012
Previous PCI 8 (5.6%) 99 (3.9%) 0.38
Killip class III or IV 23 (16.1%) 37 (1.5%) <0.001
Primary PCI (<12 hrs) 121 (84.0%) 2,198 (87.6%) 0.20
Multivessel treatment 8 (5.6%) 103 (4.1%) 0.39
Number of lesions treated per patient 1.2±0.5 1.2±0.4 0.50
Treatment of LAD 64 (44.4%) 1,049 (41.8%) 0.54
Total stent length per patient (mm) 30.7±16.6 27.7±14.6 0.019
Maximal stent diameter (mm) 3.2±0.4 3.2±0.4 0.97
TIMI flow 0-2 before PCI 119 (83.8%) 2,069 (82.8%) 0.82
Final TIMI flow 0-2 29 (20.4%) 128 (5.1%) <0.001
Thrombus aspiration 96 (66.7%) 1,604 (63.9%) 0.53
Drug-eluting stent allocation 65 (45.1%) 1,261 (50.2%) 0.27
Any dual antiplatelet therapy 136 (94.4%) 2,363 (94.1%) 1.00
CK peak value 2,935.3±2,867.7 2,123.3±1,993.1 <0.001
Values are n (%) or mean±SD. CAD: coronary artery disease; CK: creatine kinase; LAD: left 
anterior descending artery; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; TIMI: Thrombolysis In Myocardial Infarction
all-cause death or any reinfarction after primary PCI were older, 
more likely to be female, and more frequently had increased heart 
rate, hypertension, non-smoking habits, diabetes mellitus, impaired 
left ventricular ejection fraction, previous MI, Killip class III or 
IV, longer stent length, final TIMI flow 0-2, and higher CK peak 
value. Independent predictors of all-cause death or any reinfarction 
after multivariable analysis are shown in Figure 1 and comprise in 
decreasing order: Killip class III or IV (OR 5.11, 95% CI: 2.48-
10.52), left ventricular ejection fraction <0.30 (OR 4.77, 95% CI: 
2.10-10.82), final TIMI flow 0-2 (OR 1.93, 95% CI: 1.05-3.54), 
hypertension (OR 1.69, 95% CI: 1.11-2.59), age (OR 1.68, 95% CI: 
1.41-2.01), and CK peak (OR 1.25, 95% CI: 1.02-1.54).
CART ANALYSIS
Figure 2 shows the results of a CART analysis, depicting the most 
important variables which influenced the likelihood of all-cause 
death or any reinfarction in a hierarchical order through to one 
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 Odds ratio (95% CI) p-value
A. Death or reinfarction
Age* 1.68 (1.41-2.01) <0.001
Hypertension 1.69 (1.11-2.59) 0.015
LVEF <30% 4.77 (2.10-10.82) <0.001
Killip class III or IV 5.11 (2.48-10.52) <0.001
TIMI flow 0-2 after PCI 1.93 (1.05-3.54) 0.033
CK peak value 1.25 (1.02-1.54) 0.035
 0.25 0.5 1 2 4 8 16
B. Definite stent thrombosis
Killip class III or IV 7.74 (2.87-20.93) <0.001
DES allocation 0.35 (0.16-0.74) <0.007
 0.25 0.5 1 2 4 8 16
C. Target lesion revascularisation
Killip class III or IV 2.88 (1.17-7.06) 0.021
Total stent length* 1.24 (1.11-1.38)  <0.001
DES allocation 0.34 (0.21-0.54) <0.001
 0.25 0.5 1 2 4 8 16
 Odds ratio
 Lower risk Higher risk
Figure 1. Independent predictors of adverse events. Multivariate 
analysis of predictors of (A) all-cause death or any reinfarction, (B) 
definite stent thrombosis, and (C) target lesion revascularisation. 
CK: creatine kinase; DES: drug-eluting stent; LVEF: left ventricular 
ejection fraction; OR: odds ratio; TIMI: Thrombolysis In Myocardial 
Infarction. *OR per 10 units increase for age (year) and total stent 
length (mm). **OR per log-transformed CK peak value.
n=1,801
6.0%
(111/1,801)36.5%
(15/41)
14.7%
(30/204)
5.2%
(96/1,760)
30%
(6/20)
3.2%
(49/1,556)
6.5%
(5/77) 2.6%
(38/1,459)
2.8%
(43/1,536)
Final TIMI flow 3Final TIMI flow 0-2
LVEF≥30%LVEF<30%
Age≤80Age>80
Killip class I-IIKillip class III-IV
Figure 2. CART model of predictors of all-cause death or reinfarction. CART analysis showing in a hierarchical order the most important 
variables influencing the likelihood of all-cause death or reinfarction at one year. LVEF: left ventricular ejection fraction; TIMI: Thrombolysis 
In Myocardial Infarction
year. Killip class was the strongest predictor followed by age, left 
ventricular ejection fraction, and final TIMI flow 0-2. A patient 
with Killip class I or II, age ≤80, left ventricular ejection fraction 
≥30%, and final TIMI 3 flow has a one-year mortality as low as 
2.6%. Conversely, a patient with Killip class III or IV, age >80, 
left ventricular ejection fraction <30%, and final TIMI 0-2 flow has 
a considerably increased risk of all-cause death or any reinfarction 
ranging from 6.5% to 36.5% at one year.
PREDICTORS OF STENT THROMBOSIS
Baseline clinical, angiographic, and procedural characteristics accord-
ing to the occurrence of definite ST at one year are summarised in 
Table 3. Patients suffering definite ST more frequently presented with 
Killip class III or IV and were less frequently treated with DES. All 
definite ST events among patients with Killip class III or IV occurred 
within six days. After multivariable analysis, Killip class III or IV (OR 
7.74, 95% CI: 2.87-20.93) and use of DES (OR 0.35, 95% CI: 0.16-
0.74) emerged as independent predictors of definite ST (Figure 1).
PREDICTORS OF TARGET LESION REVASCULARISATION
Baseline clinical, angiographic, and procedural characteristics 
according to the occurrence of TLR at one year are summarised 
in Table 4. Patients undergoing TLR more frequently had previous 
PCI and Killip class III or IV, had a higher number of lesions to be 
treated resulting in longer total stent length, and had less frequently 
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received DES. Independent predictors of TLR after multivariable 
analysis are shown in Figure 1, and include Killip class III or IV 
(OR 2.88, 95% CI: 1.17-7.06), stent length (OR 1.24, 95% CI: 1.11-
1.38), and DES allocation (OR 0.34, 95% CI: 0.21-0.54).
Discussion
The findings of this analysis reporting predictors of adverse events 
among STEMI patients undergoing contemporary primary PCI in 
two large-scale randomised trials can be summarised as follows:
–  One-year rates of all-cause death and any reinfarction are rela-
tively low in the contemporary primary PCI era.
–  Killip class III or IV remains the strongest predictor of all-cause 
death or any reinfarction, definite ST, and TLR.
–  The use of DES independently predicts a lower risk of TLR and 
definite ST as compared with BMS.
The introduction of reperfusion strategies with the use of fibrino-
lytic agents as well as aspirin have significantly reduced mortality 
in STEMI patients19,20. More recently, mechanical reperfusion by 
means of primary PCI with stenting, in conjunction with potent 
platelet inhibitors, has further reduced in-hospital mortality to as 
low as 3%. It is worth noting that the decline in early mortality was 
consistently observed in nationwide surveys in the United States 
and Europe21,22. However, there is a paucity of information on pre-
dictors of all-cause death and reinfarction among patients with 
STEMI undergoing contemporary reperfusion with primary PCI.
PREDICTORS OF ALL-CAUSE DEATH AND ANY REINFARCTION
The present analysis shows that independent predictors of all-cause 
death and any reinfarction have not changed significantly despite 
changes in reperfusion and adjunctive therapy. Killip class at pres-
entation was identified as a predictor of mortality in the fibrinolysis 
era, as reported in the GUSTO-I and TIMI trials5,23. Similar find-
ings have been observed in the BMS era (CADILLAC), and more 
recently in the HORIZONS-AMI trial comparing early-generation 
Table 4. Baseline characteristics of patients with and without 
target lesion revascularisation at one year.
TLR
Yes (N=96) No (N=2,559) p-value
Age (yrs)** 62.9±10.7 60.9±12.2 0.11
Male gender 83 (86.5%) 2,079 (81.2%) 0.23
Body mass index (kg/m2)** 27.9±3.9 27.3±4.0 0.15
Heart rate on admission** 76.0±14.8 76.5±16.7 0.73
Blood pressure - systolic (mmHg)** 127.3±5.6 127.6±23.3 0.90
Hypertension 52 (54.2%) 1,217 (47.6%) 0.21
Family history of CAD 30 (32.3%) 595 (24.5%) 0.09
Smoking at baseline 44 (45.8%) 1,287 (50.6%) 0.41
Dyslipidaemia 46 (47.9%) 1,261 (49.4%) 0.84
Diabetes mellitus 21 (21.9%) 411 (16.1%) 0.16
Left ventricular ejection fraction <30% 2 (2.4%) 39 (1.9%) 0.67
Previous MI 7 (7.3%) 136 (5.3%) 0.36
Previous PCI 9 (9.4%) 98 (3.8%) 0.014
Killip class III or IV 6 (6.3%) 54 (2.1%) 0.020
Primary PCI (<12 hrs) 88 (91.7%) 2,231 (87.3%) 0.27
Multivessel treatment 8 (8.3%) 103 (4.0%) 0.06
Number of lesions treated per patient 1.3±0.6 1.2±0.4 0.002
Treatment of LAD 42 (43.8%) 1,071 (41.9%) 0.75
Total stent length per patient (mm)** 33.6±17.2 27.7±14.6 <0.001
Maximal stent diameter (mm) 3.2±0.5 3.2±0.4 0.12
TIMI flow 0-2 before PCI 72 (75.8%) 2,116 (83.1%) 0.07
Final TIMI flow 0-2 5 (5.2%) 152 (6.0%) 1.00
Thrombus aspiration 58 (60.4%) 1,642 (64.2%) 0.45
Drug-eluting stent allocation 25 (26.0%) 1,301 (50.8%) <0.001
Any dual antiplatelet therapy 94 (97.9%) 2,405 (94.0%) 0.12
CK peak value*** 2,275.1±2,441.2 2,164.7±2,044.0 0.64
Values are n (%) or mean±SD. CAD: coronary artery disease; CK: creatine kinase; LAD: left 
anterior descending artery; MI: myocardial infarction; PCI: percutaneous coronary intervention; 
TIMI: Thrombolysis In Myocardial Infarction; TLR: target lesion revascularisation
Table 3. Baseline characteristics of patients with and without 
definite stent thrombosis at one year.
Definite stent thrombosis
Yes (N=35) No (N=2,620) p-value
Age (yrs)** 61.3±10.5 60.9±12.2 0.85
Male gender 31 (88.6%) 2,131 (81.3%) 0.38
Body mass index (kg/m2)** 28.2±4.2 27.3±4.0 0.20
Heart rate on admission** 75.7±17.1 76.5±16.7 0.78
Blood pressure - systolic (mmHg)** 122.3±25.7 127.7±23.4 0.19
Hypertension 19 (54.3%) 1,250 (47.7%) 0.50
Family history of CAD 11 (34.4%) 614 (24.6%) 0.22
Smoking at baseline 16 (45.7%) 1,315 (50.5%) 0.61
Dyslipidaemia 16 (45.7%) 1,291 (49.4%) 0.76
Diabetes mellitus 7 (20.0%) 425 (16.2%) 0.49
Left ventricular ejection fraction <30% 1 (3.2%) 40 (1.9%) 0.46
Previous MI 4 (11.4%) 139 (5.3%) 0.12
Previous PCI 2 (5.7%) 105 (4.0%) 0.65
Killip class III or IV 5 (14.3%) 55 (2.1%) 0.001
Primary PCI (<12 hrs) 32 (91.4%) 2,287 (87.4%) 0.61
Multivessel treatment 0 (0.0%) 111 (4.2%) 0.40
Number of lesions treated per patient 1.1±0.4 1.2±0.4 0.64
Treatment of LAD 12 (34.3%) 1,101 (42.0%) 0.39
Total stent length per patient (mm)** 29.6±10.8 27.8±14.8 0.49
Maximal stent diameter (mm) 3.3±0.5 3.2±0.4 0.26
TIMI flow 0-2 before PCI 30 (85.7%) 2,158 (82.8%) 0.82
Final TIMI flow 0-2 2 (5.7%) 155 (5.9%) 1.00
Thrombus aspiration 26 (74.3%) 1,674 (63.9%) 0.22
Drug-eluting stent allocation 9 (25.7%) 1,317 (50.3%) 0.006
Any dual antiplatelet therapy 34 (97.1%) 2,465 (94.1%) 0.72
CK peak value*** 2,672.0±2,329.6 2,161.5±2,055.0 0.17
Values are n (%) or mean±SD. CAD: coronary artery disease; CK: creatine kinase; LAD: left 
anterior descending artery; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; TIMI: Thrombolysis In Myocardial Infarction
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paclitaxel-eluting stents and BMS7,24,25. The fact that Killip class 
remains the strongest predictor of all-cause death and any reinfarction, 
irrespective of left ventricular function and extent of coronary artery 
disease at baseline, reflects the degree of haemodynamic compromise 
in these patients which can be recognised easily on clinical grounds.
In addition to Killip class, other predictors of death and reinfarction 
identified in our analysis included age, hypertension, left ventricular 
ejection fraction, final TIMI flow and CK peak value, which have 
traditionally been considered major risk factors of ischaemic adverse 
events after STEMI and have been consistently identified in previous 
reports as predictors of death and reinfarction among STEMI patients 
treated with fibrinolysis as well as primary PCI5,7,23,26.
PREDICTORS OF STENT THROMBOSIS AND TARGET LESION 
REVASCULARISATION
Beyond Killip class, other independent predictors of definite ST 
and TLR are all device-related. Given the fact that all definite ST 
among patients with Killip class III or IV occurred within six days of 
PCI, it appears important to ensure optimal procedural results avoid-
ing residual dissections, inadequate stent expansions, and to install 
adequate antithrombotic treatment during and after the procedure.
Importantly, DES allocation predicted a reduced risk of both ST 
and TLR. The higher effectiveness of DES compared with BMS, 
leading to a reduced risk of restenosis and repeat revascularisa-
tion procedures, has been evidenced since the introduction of DES 
in clinical practice among patients with stable angina as well as 
STEMI13. However, safety concerns were raised with respect to 
the use of early-generation sirolimus-eluting and paclitaxel-eluting 
stents in the setting of STEMI27. Two recent network meta-analyses 
have reported a lower risk of ST with new-generation DES compared 
with BMS28,29. Similar results were observed in the EXAMINATION 
trial30. These findings can be explained at least in part by a lower 
thrombogenicity observed in vitro with new-generation DES com-
pared with BMS31. In line with these recent reports, the present large-
scale patient-level analysis shows that DES allocation reduced the 
risk of definite ST by 70% in patients with STEMI at one year. Of 
note, BioMatrix and Gazelle have identical stent platforms, and the 
same applies to XIENCE V and MULTI-LINK VISION. Therefore, 
the differences between the DES used and their BMS comparators 
were limited to polymer coatings and antiproliferative agent release. 
Whether this benefit persists beyond the first year after PCI will need 
to be confirmed by longer-term follow-up of available trials as well 
as by future studies powered for safety endpoints.
As it relates to device effectiveness, stent length independently 
predicted TLR in our analysis. Several reports have associated stent 
length with an increased risk of repeat revascularisation after PCI 
in patients with stable angina and STEMI32,33. This may be related 
to the higher degree of vascular injury after implantation of longer 
and/or overlapping metallic stents34.
Study limitations
Some limitations of the present analysis deserve discussion. 
First, time from symptom onset to reperfusion was not available. 
However, both the COMFORTABLE AMI and EXAMINATION 
trials were conducted in European countries with developed 
STEMI networks. Therefore, one can assume a low degree of 
variability in time-to-reperfusion across the centres involved in 
the two trials. Second, baseline characteristics captured in the 
COMFORTABLE AMI and EXAMINATION trials were not 
identical. Therefore, we cannot exclude that unmeasured varia-
bles, such as renal failure and anaemia, might have emerged as 
independent predictors of adverse events if available for analysis. 
Third, high-volume European tertiary centres recruited patients in 
the COMFORTABLE AMI and EXAMINATION trials. For this 
reason, our findings may not be generalisable to different health-
care settings. Fourth, the currently available universal definition 
of MI was not applied in this study which would probably have 
resulted in somewhat higher event rates, particularly during the 
follow-up phase. However, one of the strengths of this pooled 
analysis is the uniform definition as well as the adjudication of 
the endpoint MI in both studies. Fifth, the aim of this analysis 
was to identify baseline predictors of adverse events. Evaluating 
the impact of any changes in adherence to medications over time 
was beyond the scope of this analysis. Finally, clinical follow-
up was limited to one year. It cannot be excluded that predictors 
of longer-term outcomes might differ from the ones identified in 
this analysis. Nevertheless, it is notable that over 60% of adverse 
events in patients with STEMI occur during the first year of fol-
low-up35. Therefore, predictors of one-year outcomes remain of 
importance to identify high-risk subsets among patients with 
STEMI undergoing percutaneous reperfusion in the contempo-
rary era of primary PCI.
Conclusions
Killip class remains the strongest predictor of all-cause death or 
reinfarction among STEMI patients undergoing primary PCI. DES 
use independently predicts a lower risk of TLR and definite ST 
compared with BMS.
Impact on daily practice
Patients with ST-segment elevation myocardial infarction 
(STEMI) undergoing primary percutaneous coronary interven-
tion (PCI) remain at high risk of adverse events, including death, 
reinfarction, stent thrombosis and repeat revascularisation. This 
underlines the need to identify predictors of impaired clinical out-
comes in order to recognise higher-risk patients in contemporary 
practice of primary PCI. According to our findings, Killip class 
remains the strongest predictor of death or reinfarction in STEMI 
patients undergoing primary PCI, which highlights that a sim-
ple clinical assessment remains of key importance in this setting. 
In addition, the use of DES independently predicts a lower risk 
of definite stent thrombosis and target lesion revascularisation 
compared with bare metal stents, suggesting that DES should be 
considered the standard of care in STEMI patients undergoing 
primary PCI. 
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